Optaflu

Influenza (Flu)
Types
Avian (A/H5N1 subtype) · Canine Equine · Swine (A/H1N1 subtype)
Vaccines
2009 pandemic (Pandemrix) ACAM-FLU-A · Fluzone · Influvac Live attenuated (FluMist) · Optaflu
Treatment
Amantadine · Arbidol · Laninamivir Oseltamivir · Peramivir · Rimantadine Vitamin D · Zanamivir
Pandemics
2009 Swine · 1968–1969 Hong Kong · 1918
Outbreaks
2008 West Bengal 2007 Bernard Matthews H5N1 2007 Australian equine 2006 H5N1 India · 1976 swine flu
See also
Flu season · Influenza evolution Influenza research Influenza-like illness
v · d · e

Optaflu is a cell culture derived influenza vaccine manufactured by Novartis.

History

On April 27, 2007 Novartis received a positive opinion supporting European Union approval of Optaflu. It is the first influenza vaccine made in a mammalian cell line, rather than chicken eggs.^[1] The vaccine will be manufactured in Holly Springs, North Carolina. The United States government is providing $500 million in construction costs and guaranteed vaccine purchases.^[2]

References

1. ^ "Optaflu, the Novartis cell culture-derived influenza vaccine, receives positive opinion supporting European Union regulatory approval". Novartis. http://www.novartis-vaccines.com/press-room/news/20070427_Optaflu.shtml. Retrieved 2009-04-29. 
2. ^ Pollack, Andrew (2009). "Swine Flu Vaccine May Be Months Away, Experts Say". New York Times. http://www.nytimes.com/2009/04/29/business/economy/29vaccine.html?ref=health. Retrieved 2009-04-29. "But Novartis is building a cell culture flu vaccine factory in Holly Springs, N.C., which might be ready for use in 2010 or 2011. The federal government is providing nearly $500 million in construction costs and guaranteed vaccine purchases."